drugset / Trial / NCT00999544

Aprepitant Effects on Oxycodone Response

NCT00999544

RandomizedCrossoverTriple-blindBasic science

Summary

Addressing the issue of opioid dependence and tolerance has public health implications for the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in modulating both the acute and chronic response to opioids. The objective of this study is to determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse liability and reinforcing effects.

Timeline

Start
2009-10
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified 40 mg Oral
Subject Aprepitant Other / unclassified 200 mg Oral
Subject Oxycodone Other / unclassified 15 mg Intranasal
Subject Oxycodone Other / unclassified 20 mg Oral
Subject Oxycodone Other / unclassified 30 mg Intranasal
Subject Oxycodone Other / unclassified 40 mg Oral

Indications